Coherus Oncology
CHRS
201 hedge funds and large institutions have $1.23B invested in Coherus Oncology in 2021 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 54 increasing their positions, 72 reducing their positions, and 22 closing their positions.
77% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 22
57% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $726K
7% more funds holding
Funds holding: 187 → 201 (+14)
0.71% more ownership
Funds ownership: 99.53% → 100.24% (+0.71%)
0% more capital invested
Capital invested by funds: $1.22B → $1.23B (+$5.73M)
25% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.6M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$12.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$11M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.78M |
| 5 |
BlackRock
New York
|
+$5.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$14.4M |
| 2 |
JP Morgan Chase
New York
|
-$8.41M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.64M |
| 4 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$3.82M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.72M |
CHRS Hedge Fund Activity: Q4 2021 in Review
201 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2021, worth a combined $1.23B — up 0.47% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CHRS positions and 22 closed out — a net gain of 17 holders — while 54 added to existing stakes and 72 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $19.6M. The largest seller was Bank of Montreal, cutting an estimated $14.4M.
- 201 institutional investors held Coherus Oncology (CHRS) as of Q4 2021, up from 187 in Q3 2021.
- Funds reported $1.23B of Coherus Oncology stock for Q4 2021, up 0.47% quarter-over-quarter.
- 39 funds opened new Coherus Oncology positions in Q4 2021 and 22 closed out, a net change of +17 holders.
- The largest Coherus Oncology buyer in Q4 2021 was AllianceBernstein, an estimated $19.6M added.
- The largest Coherus Oncology seller in Q4 2021 was Bank of Montreal, an estimated $14.4M sold.
Based on aggregated 13F filings for Q4 2021.